PEOPLE - UK private equity and venture capital firm 3I makes appointment:
This article was originally published in Clinica
Executive Summary
As part of its aim to increase its investment in healthcare, London-based UK private equity and venture capital firm 3i has appointed Peter Chambre as an industrialist-in-residence. Mr Chambre has 13 years' experience of leading healthcare companies, including Bespak (CEO), the Cambridge Antibody Technology Group (CEO) and Celera Genomics Group (COO). As part of 3i's industrialist-in-residence programme, Mr Chambre will identify, evaluate and complete deals in the healthcare sector, and provide significant levels of leadership assistance to businesses that are backed by 3i. Mr Chambre is currently a non-executive director of BTG (life sciences, UK) and Spectris (precision engineering, UK).
You may also be interested in...
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.